HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Park, S. Articles by Soumerai, S. B. Search for Related Content PubMed Articles by Park, S. Articles by Soumerai, S. B.

Authors’ reply

Korea Health Industry Development Institute, 57-1 Noryangjin-Dong, Dongjak-GU, Seoul 156-800, Republic of Korea.

D. Ross-Degnan, A. S. Adams and J. Sabin

Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, USA

P. Kanavos

London School of Economics and Political Science, London, UK

S. B. Soumerai

Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, USA

Correspondence: E-mail: sylviap{at}khidi.or.kr

EDITED BY KIRIAKOS XENITIDIS and COLIN CAMPBELL

We agree with the comments of Grover & Kulhara on the lack of information about the specific reasons for the prescription of antiparkinsonian drugs in our observational study. We have stated that such prescribing might have been influenced by factors other than the occurrence of EPS. However, previous naturalistic studies have shown that the use of antiparkinsonian medication was highly correlated with clinical indices of EPS when patients were prescribed antipsychotics (Barak et al, 2002; Bobes et al, 2003; Montes et al, 2003). In addition, the sudden change in the incidence of antiparkinsonian drug use following introduction of atypical antipsychotics in the entire population (not just among patients who switched type of antipsychotic therapy) makes it unlikely that physician prescribing habits were a strong alternative explanation for our findings.

Since we observed the same patients over time in the analysis of drug switching, changes in antiparkinsonian drug prescribing following the switch could be explained by the differential effects of antipsychotics on EPS.

Nevertheless, antiparkinsonian drug prescribing is only a marker of EPS and cannot perfectly reflect the incidence of EPS. Owing to the limitation of our data-set (which did not include indications for prescriptions), we cannot exclude the possibility that some patients may have been prescribed antiparkinsonian medication because they had Parkinson’s disease, not because they had EPS caused by antipsychotics.

Grover & Kulhara question why we included only 266 GPs in this study. We selected from the GPRD only those patients who had been diagnosed with schizophrenia and prescribed antipsychotics between 1992 and 2000. Therefore 6356 patients who met those requirements and their 266 general practices were included in the study.

Grover & Kulhara raise the possibility that patients might have taken both classes of antipsychotics simultaneously. We examined the effects of switching antipsychotics on antiparkinsonian drug prescribing by classifying patients into two groups. We defined the TA group as patients who had been prescribed typical antipsychotics with no atypical antipsychotic use before the switch, completely stopped typical antipsychotics and subsequently switched to atypical antipsychotics, with no typical antipsychotic use for at least 2 years after the switch. The TT group included patients who were prescribed one typical antipsychotic (e.g. chlorpromazine) then switched to a different typical antipsychotic (e.g. haloperidol), and who never received an atypical antipsychotic during the study period. Therefore, by definition, no patients in our study were receiving a combination of both classes of antipsychotics.

REFERENCES

Barak, Y., Shamir, E. & Weizman, R. (2002) Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study. Journal of Clinical psychopharmacology, 22, 115 -120.[CrossRef][Medline]

Bobes, J., Gilbert, J., Ciudad, A., et al (2003) Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 27, 473 -481.

Montes, J. M., Ciudad, A., Gascon, J., et al (2003) Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 27, 667 -674.

This Article Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Park, S. Articles by Soumerai, S. B. Search for Related Content PubMed Articles by Park, S. Articles by Soumerai, S. B.